A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost.
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes pain and stiffness in the joints, fatigue, bone damage and, eventually, loss of mobility. RA afflicts around 1% of people in the western world; in Belgium, 80,000 to 100,000 people currently live with the disease.
Because there is no known cure for RA, physicians focus treatment on suppressing disease activity. Therapies have improved in recent years, and clinical studies show that intensive treatment of early RA can prevent joint damage and improve patients’ quality of life.
In the two-year study, called ‘CareRA’ (Care in early RA), researchers and clinicians in the rheumatology unit at University Hospitals Leuven examined various therapies for early RA. Their goal: to find the optimal combination and dosage of three commonly prescribed antirheumatic drugs (methotrexate, sulfasalazine and leflunomide) in combination with glucocorticoids (a class of steroid hormones).
The researchers divided 290 early RA patients into three treatment groups. Each group received a different combination therapy: ‘COBRA Classic’ (methotrexate, sulfasalazine and a high first dose of glucocorticoids), ‘COBRA Slim’ (methotrexate and a moderate dose of glucocorticoids) or ‘COBRA Avant-Garde’ (methotrexate, leflunomide and a moderate dose of glucocorticoids).
Fewer side effects
All three strategies showed a similarly high efficacy: disease remission was achieved in 7 in 10 patients after 16 weeks of treatment. But results for the strategies varied significantly when it came to side effects.
The new COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies – and was just as effective. The strategy would also be easier to implement in daily practice because it is less complicated.
A broader use of this strategy would lead to higher remission rates in the global early RA population and would probably reduce the need for expensive second-line antirheumatic treatment, say the researchers.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Know here how early detection of rheumatoid arthritis is possibleon October 15, 2019 at 4:20 am
Rheumatoid arthritis is an autoimmune disease in which the immune system of the body (that’s responsible of attacking disease-causing foreign objects) mistakenly starts attacking the joints. This ...
- Fish oil alleviates rheumatoid arthritis, Royal Adelaide Hospital research showson October 14, 2019 at 3:27 pm
Fish oil is so good for swollen joints it can eliminate the need for medication in patients with rheumatoid arthritis, Adelaide research shows. But whatever you do, don’t smoke, especially if you are ...
- Women more prone to rheumatoid arthritis than men, says experton October 12, 2019 at 8:14 pm
Rheumatoid arthritis has a prevalence of about 1 per cent worldwide and can affect people of all age groups, including children and adolescents. Women are more prone to get affected than men, said ...
- World Arthritis Day 2019: Know The Link Between Rheumatoid Arthritis And Depressionon October 11, 2019 at 10:50 pm
A person with rheumatoid arthritis (RA) may not seem to fit the usual profile of an "arthritis" patient since this word is usually associated with older people. RA, however, is a type of arthritis ...
- Women are more likely to be affected with Rheumatoid Arthritis (RA) than menon October 11, 2019 at 1:14 am
Rheumatoid Arthritis is a chronic, debilitating disease that causes a major impact on a patient’s quality of life and socio-economic productivity. RA affects about 1 per cent of the total population.
- Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritison October 10, 2019 at 3:44 pm
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, ...
- Danielle Collins reveals diagnosis of rheumatoid arthritison October 10, 2019 at 2:48 am
Danielle Collins has begun treatment for rheumatoid arthritis, a chronic inflammatory condition that causes pain and swelling in the body's joints. The American, 25, who is the WTA World No.33 and ...
- Danielle Collins diagnosed—but not defeated—by rheumatoid arthritison October 9, 2019 at 5:40 pm
Danielle Collins, a semifinalist at this year’s Australian Open, announced Wednesday on Instagram that she suffers from rheumatoid arthritis. While receiving news of having a chronic inflammatory ...
- Collins says she has rheumatoid arthritison October 9, 2019 at 3:57 pm
(Reuters) - American Danielle Collins on Wednesday said she has begun treatment for rheumatoid arthritis, an immune disorder that can cause debilitating swelling and pain in the joints. The Florida ...
- Palindromic rheumatism as part of the rheumatoid arthritis continuumon October 8, 2019 at 10:23 am
Palindromic rheumatism is a distinctive syndrome that has a long-recognized association with rheumatoid arthritis (RA). Palindromic rheumatism is characterized by intermittent flares of pain, erythema ...
via Bing News